



AVITA Medical Investor Briefing

- ***9am Friday 1 October AEST***

Valencia, Calif., USA, MELBOURNE, Australia, September 27, 2021— AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) CEO, Dr. Michael Perry will provide an online investor briefing at 9:00 am Friday 1 October 2021 Australian Eastern Standard Time. The presentation will be focused on Australian shareholders and investors; other interested parties are also invited to participate.

The presentation will cover highlights from AVITA Medical's successful 2021 fiscal year, including a 105% year-over-year increase in revenue and FDA approval of AVITA Medical's amended pivotal Vitiligo study design. Projected key milestones for fiscal year 2022 will also be reviewed.

To register for the presentation, please follow this Zoom link:

https://us02web.zoom.us/webinar/register/WN_9fXpyoKtS0WBjnxArpVBbQ

Participants are invited to submit questions via the registration page or during the webinar. A replay will be available on the AVITA Medical website, www.avitamedical.com following the presentation.

ABOUT AVITA MEDICAL, INC.

AVITA Medical is a regenerative medicine company with a technology platform positioned to address unmet medical needs in burns, chronic wounds, and aesthetics indications. AVITA Medical's patented and proprietary collection and application technology provides innovative treatment solutions derived from the regenerative properties of a patient's own skin. The medical devices work by preparing a RES[®] REGENERATIVE EPIDERMAL SUSPENSION, an autologous suspension comprised of the patient's skin cells necessary to regenerate natural healthy epidermis. This autologous suspension is then sprayed onto the areas of the patient requiring treatment.

AVITA Medical's first U.S. product, the RECELL[®] System, was approved by the U.S. Food and Drug Administration (FDA) in September 2018. The RECELL System is indicated for use in the treatment of acute thermal burns. The RECELL System is used to prepare Spray-On Skin[™] Cells using a small amount of a patient's own skin, providing a new way to treat severe burns, while significantly reducing the amount of donor skin required. The RECELL System is designed to be used at the point of care alone or in combination with autografts depending on the depth of the burn injury. Compelling data from randomized, controlled clinical trials conducted at major U.S. burn centers and real-world use in more than 10,000 patients globally reinforce that the RECELL System is a significant advancement over the current standard of care for burn patients and offers benefits in clinical outcomes and cost savings.

Healthcare professionals should read the INSTRUCTIONS FOR USE - RECELL® Autologous Cell Harvesting Device (<https://recellsystem.com/>) for a full description of indications for use and important safety information including contraindications, warnings, and precautions.

In international markets, our products are marketed under the RECELL System brand to promote skin healing in a wide range of applications including burns, chronic wounds, and aesthetics. The RECELL System is TGA-registered in Australia and received CE-mark approval in Europe. To learn more, visit www.avitamedical.com.

FOR FURTHER INFORMATION:

<p>U.S. Media Sam Brown, Inc. Christy Curran Phone +1-615-414-8668 christycurran@sambrown.com</p> <p>O.U.S. Media Rudi Michelson Phone +61 (0)3 9620 3333 Mobile +61 (0)411 402 737 rudim@monsoon.com.au</p>	<p>Investors Westwicke Partners Caroline Corner Phone +1-415-202-5678 caroline.corner@westwicke.com</p>
--	--